Prompt: Summarize the business model from the following text. Answer with a continuous text and with fivehundredtwelve tokens at max. Set your focus on sources of revenue , the intended customer base , products , distribution channels  and details of financing. Use only information from the following the text:

ITEM 1. BUSINESS
Overview

AngioSoma is a wellness company launching a line of nutraceutical supplements under our Soma NutraceuticalsTM identity as well as continuing to pursue the clinical stage pharmaceutical brand LiprostinTM focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (PAD).

Our lead pharmaceutical drug candidate is LiprostinTM for the treatment of peripheral artery disease, or PAD, which has completed FDA Phase I and three Phase II clinical trials. We are in discussions with several contract research organizations for completion of our FDA protocol for Phase III and submission of our new drug application for marketing in the US and its territories.

